Rani Therapeutics Holdings, Inc.
RANIHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeOperating under the Biotechnology umbrella, Rani Therapeutics Holdings, Inc. is a healthcare company. Rani Therapeutics Holdings, Inc. At a $121.6M market cap, Rani Therapeutics Holdings, Inc. ranks as a micro-cap company within healthcare. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Market Cap
$121.6M
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
-4.55
EPS (TTM)
$-0.13
EPS (Fwd)
$-0.19
ROE
-172.2%
ROA
-53.0%
Cash
$53.4M
Total Debt
$3.5M
Free CF
-$8.9M
52W Change
70.4%
Annual Financials
Cash vs Debt
Where RANI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RANI finished 10.42% below its 150-day moving average ($0.96) and 21.10% below its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RANI overbought or oversold?
At the September 3, 2026 close, RANI's RSI(14) was 58.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $53.4M in cash comfortably exceeding the $3.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$8.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -172.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RANI.